Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Diagn Cytopathol ; 25(6): 376-81, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11747234

ABSTRACT

Human polyoma virus (HPOV) infection is associated with hemorrhagic cystitis, tubulointerstitial nephritis, and renal transplant dysfunction/allograft loss. We evaluated the utility of cytologic examination to detect HPOV infection in 37 urinary cytology (UC) samples (3 bladder washings, and 34 voided samples) from 29 transplant patients, compared to electron microscopic studies (EMS). Evidence of viral infection was found in 11 specimens (30%). Five cases were diagnosed as HPOV by both UC and EMS. One was positive for HPOV by EMS only. Two cases diagnosed as HPOV by UC were demonstrated to be adenovirus (AV) with EMS. Two cases diagnosed as cytomegalovirus (CMV) by EMS had negative UC. One was called HPOV by UC; EMS in this case was negative. Compared to EMS, the sensitivity and specificity of UC for detecting HPOV were 83% and 90%, respectively, with a positive predictive value of 63% and a negative predictive value of 96%. We conclude that UC is a relatively sensitive and specific method for detecting active HPOV infection in transplant patients, and is important in light of the clinical significance of HPOV infection in transplant recipients. The sensitivity and accuracy of UC for diagnosing HPOV can be increased by adding EMS.


Subject(s)
Organ Transplantation/pathology , Polyomavirus Infections/diagnosis , Polyomavirus/isolation & purification , Postoperative Complications/diagnosis , Urine/virology , Adenoviridae/isolation & purification , Adenoviridae/ultrastructure , Adolescent , Adult , Aged , Child , Cytodiagnosis/methods , Female , Humans , Male , Microscopy, Electron , Middle Aged , Polyomavirus/ultrastructure , Polyomavirus Infections/urine , Reproducibility of Results , Sensitivity and Specificity , Transplantation, Homologous
2.
Diagn Cytopathol ; 25(1): 43-9, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11466812

ABSTRACT

Fine-needle aspiration (FNA) of the pelvis and retroperitoneum (excluding the pancreas, kidney, and adrenal masses) has not achieved its full potential as a diagnostic modality. We reviewed 68 percutaneous, radiologically guided FNAs from these locations to assess the clinical utility and complication rate of this procedure. Satisfactory material was obtained in 66 cases (97.1%), of which 37 were deemed positive (55%), 3 suspicious (4%), 4 atypical (6%), and 22 negative (32%) for malignancy; two cases (3%) were unsatisfactory. Compared to biopsy (36 patients) and clinical information, the sensitivity and specificity of FNA for malignancy were 90.2% and 100%, respectively, yielding a positive predictive value of 100% and a negative predictive value of 86.6%. The four false-negative cases (5.9%) were due to sampling error. One patient had a minor complication (hematoma) from the procedure. We conclude that FNA is the procedure of choice for detecting most malignancies in these two locations.


Subject(s)
Pelvis/pathology , Retroperitoneal Space/pathology , Biopsy, Needle , Humans , Lymphoma/diagnosis , Lymphoma/pathology , Melanoma/diagnosis , Melanoma/pathology , Pelvic Neoplasms/diagnosis , Pelvic Neoplasms/pathology , Retroperitoneal Neoplasms/diagnosis , Retroperitoneal Neoplasms/pathology , Retrospective Studies , Sarcoma/diagnosis , Sarcoma/pathology
3.
Diagn Cytopathol ; 25(2): 141-7, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11477723

ABSTRACT

ThinPrep purportedly increases the sensitivity of cervicovaginal cytology for detecting abnormal squamous and glandular cells. The value of additional slides from residual Preservcyt material to characterize difficult lesions is unknown. Fifty-eight cases were studied to determine the utility of additional slides for diagnosis and to assess cellular uniformity. In 32 (55%), repeat slides helped make a definitive diagnosis, including 18 atypical squamous cells of uncertain significance (ASCUS) reclassified as low-grade squamous intraepithelial lesion (LGSIL) (13), high-grade squamous intraepithelial lesion (HGSIL) (4), or endometrial adenocarcinoma (1); 5 LGSIL reclassified as HGSIL; 3 atypical glandular cells of uncertain significance (AGUS) reclassified as LGSIL (1) or HGSIL (2); 2 LGSIL?HGSIL classified as LGSIL; and 4 cases confirmed as LGSIL (2) or HGSIL (2). Results were compared to follow-up clinical information, including subsequent cervicovaginal samples and biopsies. The number of abnormal cells was similar between slides in most cases. We conclude that, while ThinPreps prepared from the same vial have similar numbers of abnormal cells, additional slides can be helpful for diagnosis in select cases.


Subject(s)
Vaginal Diseases/pathology , Female , Humans , Microtomy , Prospective Studies , Vagina/pathology , Vaginal Diseases/diagnosis
4.
Diagn Cytopathol ; 24(6): 403-7, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11391822

ABSTRACT

Salivary gland myoepithelioma (ME) is a neoplasm derived from myoepithelial cells that lacks the ductal and broad mesenchymal differentiation seen in the vast majority of mixed tumors. This report describes the cytologic findings of a cystic ME presenting in the midline of the dorsal tongue, a site where no salivary glands are generally present. The tumor was well circumscribed and composed of sheets of monotonous epithelioid cells without ductal cells. The cells were positive for S-100 protein and ultrastructurally had features of myoepithelial cells. The fine needle aspiration (FNA) biopsy findings, differential diagnosis, histology, immunohistochemistry, and electron microscopic features of this interesting and uncommon neoplasm are presented. To the best of our knowledge, there have been no cytologic reports of ME of the tongue.


Subject(s)
Myoepithelioma/pathology , Tongue Neoplasms/pathology , Aged , Biopsy, Needle , Diagnosis, Differential , Humans , Male , Myoepithelioma/diagnosis , Myoepithelioma/surgery , Tongue/cytology , Tongue/surgery , Tongue Neoplasms/diagnosis , Tongue Neoplasms/surgery , Treatment Outcome
5.
Diagn Cytopathol ; 23(5): 338-42, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11074630

ABSTRACT

Fibromatosis colli is a benign disorder presenting as a neck mass in neonates and older children. The differential diagnosis includes malignancies such as rhabdomyosarcoma. Neck masses in ten infants, discovered between the second and sixth week of age, were evaluated by fine-needle aspiration (FNA). The male to female ratio was 7:3. In 8 patients there was good obstetrical history. Six of the 8 patients had a difficult delivery, as indicated by breech presentation or the need for forceps. Diagnostic aspirations were performed between the second to ninth week of age. The major cytologic finding was benign spindle fibroblasts, usually arrayed in clusters. The cells possessed plump, ovoid nuclei. There were also multinucleated cells consistent with degenerating skeletal muscle fibers. Only one case demonstrated significant inflammation. FNA can provide a rapid and reliable diagnosis in fibromatosis colli. There is support for the idea that in this setting, the disorder is related to perinatal muscular trauma.


Subject(s)
Biopsy, Needle , Fibromatosis, Aggressive/diagnosis , Head and Neck Neoplasms/diagnosis , Diagnosis, Differential , Female , Humans , Infant , Infant, Newborn , Male , Muscle, Skeletal/pathology
6.
Diagn Cytopathol ; 23(5): 362-5, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11074636

ABSTRACT

Spindle-cell lipoma (SCL) is an uncommon subcutaneous soft-tissue neoplasm that usually arises in the posterior neck and shoulder of older male patients. To our knowledge, there have been only two reports describing the cytologic findings of this benign tumor, only one of which was confirmed by subsequent histologic examination. We report on a SCL of the occipital scalp in a 62-yr-old man diagnosed by fine-needle aspiration. Air-dried and alcohol-fixed smears revealed scattered clusters of mildly pleomorphic spindled cells admixed with mature adipocytes, numerous mast cells, and small fragments of collagen. The diagnosis was confirmed by histologic sections and immunohistochemical studies for CD34 and bcl-2 oncoprotein. Cytomorphologic features of SCL and a review of the literature are presented.


Subject(s)
Biopsy, Needle , Lipoma/diagnosis , Antigens, CD34/analysis , Humans , Immunohistochemistry , Male , Middle Aged , Proto-Oncogene Proteins c-bcl-2/analysis , Scalp
7.
Diagn Cytopathol ; 23(6): 417-21, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11074650

ABSTRACT

True thymic hyperplasia (TH) is an age-dependent increase in size and weight of the thymus gland, which by definition maintains a normal histologic architecture. TH can mimic other important diseases, including lymphofollicular hyperplasia, thymoma, lymphoma, and germ-cell tumors. Traditionally, separating these entities has required a formal surgical biopsy. Given that many of these conditions occur in children, this can be a traumatic experience for both the patient and family members. Fine-needle aspiration biopsy has the distinct advantage of being able to obtain diagnostic material without requiring general anesthesia. We are aware of only one previously reported case of an enlarged thymus being subjected to aspiration cytology. We therefore present a case of thymic hyperplasia in a 5-mo-old child diagnosed by combined radiologic and cytologic parameters, including flow cytometric analysis.


Subject(s)
Flow Cytometry/methods , Thymus Gland/pathology , Thymus Hyperplasia/pathology , Biopsy, Needle , Diagnosis, Differential , Female , Germinoma/pathology , Humans , Infant , Lymphoma/pathology , Magnetic Resonance Imaging , Pseudolymphoma/pathology , Thymoma/pathology , Thymus Gland/diagnostic imaging , Thymus Hyperplasia/diagnostic imaging , Thymus Neoplasms/pathology , Tomography, X-Ray Computed
8.
Acta Cytol ; 44(4): 618-24, 2000.
Article in English | MEDLINE | ID: mdl-10934956

ABSTRACT

OBJECTIVE: To compare diagnostic discrepancies and screening parameters between conventional (CP) and ThinPrep (TP) (Cytyc Corporation, Boxborough, Massachusetts, U.S.A.) cervicovaginal samples using Pathfinder (Neopath, Redmond, Washington, U.S.A.). STUDY DESIGN: Pathfinder tracked average screening time, percent slide coverage and percent overlap of viewing fields for CP and TP. False negative rate (FNR) was determined by rescreening 10% of random and high-risk negative cases. CP and TP FNR with Pathfinder were compared to control groups without Pathfinder. RESULTS: A total of 46,393 Pathfinder cases were evaluated (43,354 CP, 3,039 TP) as compared to 62,981 without Pathfinder (60,307 CP, 2,674 TP). FNR was calculated for 12,983 negatives. Using Pathfinder resulted in a significant reduction in FNR for CP atypical squamous cells of undetermined significance and atypical glandular cells of undetermined significance cases. No decrease in FNR was observed for CP squamous intraepithelial lesions or for TP cases. TP slides were screened 66 seconds faster on average than CP. With electronic feedback, mean percent slide coverage and percent overlap were similar between CP and TP cases. Without feedback, coverage dropped and overlap increased slightly for both CP and TP. Technologists screened faster with feedback, saving an average of 50 seconds on CP and 41 seconds on TP. CONCLUSION: Pathfinder significantly reduced FNR for CP but not TP. Technologists screened TP significantly faster than CP while maintaining similar coverage and overlap. Pathfinder feedback itself may decrease screening time.


Subject(s)
Cervix Uteri/pathology , Vaginal Smears/instrumentation , Female , Humans , Mass Screening/instrumentation , Mass Screening/standards
9.
Diagn Cytopathol ; 23(1): 1-5, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10907923

ABSTRACT

With the introduction of new technologies we often see a pattern of development. As a useful technology moves into the public sector there is often an episode of wild enthusiasm and uncritical acceptance, followed by a time of progressive disillusionment. However, with time and experience, a proper place for the method becomes established. Thin-layer technology is certainly an improvement and solves many of our preanalytical problems; however, it introduces some difficulties of its own. The rounding up of cells in liquid fixation makes cells of high-grade lesions smaller than they would be on a conventional preparation. The abnormal cells are often separated. For both of these reasons they may be overlooked. Furthermore, benign glandular cells can take on an ominous appearance. These differences in conventional and thin-layer morphology are proving to be a fruitful area for publication. Thin-layer technology cannot be all things to all situations, and this is especially true in body fluid and fine-needle cytomorphology. In our experience, while occasionally helpful, the thin-layer technique should not be the primary method for diagnosis in nongynecologic specimens. Time and effort would be better spent on trying to educate select clinicians on how to obtain better samples than to totally convert to thin-layer methodologies. Regarding FNA, the patient is best served when the pathologist is directly involved with the initial sample acquisition. Reimbursement is available for immediate sample interpretation, so funding should be available for staffing if an institution has the interest. For the record, we believe that liquid fixation and thin-layer methodology should not be the primary method for FNA, unless circumstances are absolutely prohibitive. An important problem with thin-layer technology lies with its added cost. Thin-layer interposes another series of steps into cytologic sample preparation. There is additional labor, additional time, another machine in the laboratory, and the significant cost of the reagents. In a situation where the price of a cytologic test is already close to margin, costs of the vial, filter, and preservative throw the test into unprofitability. Price structures have to be changed. Some institutions are waiting until there is more competition in the market and costs decrease. Alternatively, a lot of effort has been expended in trying to get government and other groups to accept the additional costs of the new test for gynecologic examinations, and many payers seem to be falling in line to accept the methodology, secondary to clinician and patient demand. Basic questions about ancillary technologies and gynecologic samples remain to be answered. Cytology is big business. Every year a significant segment of the population has a Pap smear performed. Hardly any other laboratory test can claim the volume of activity of the cervical smear. Any business that can hook into that market stands to prosper. Since the Pap smear has some well-publicized problems, the door is open for technology to nibble away at a few percentage points of false negativity. We are far from the first to ask if we can afford the incremental improvements of thin-layer and other ancillary technologies. There is a conundrum. Government, insurance companies, and our administrators are calling for us to hold back cost increases in medical care. Alternatively, these new technologies, patient demand for the perfect test, increased regulatory oversight, and legal challenges are increasing the cost of doing business. We do not know how to respond to the often-voiced fear that these ancillary technologies increase the cost of cytology services beyond some patients' ability to pay. In this confusion, we do know that we should use the best test to get the most accurate answer for our patients. In selected scenarios this may mean that we will have to accept the cost and follow thin-layer technology.


Subject(s)
Carcinoma, Squamous Cell/diagnosis , Papanicolaou Test , Uterine Cervical Neoplasms/diagnosis , Vaginal Smears/methods , Breast Neoplasms/diagnosis , Carcinoma, Squamous Cell/pathology , Female , Humans , Reagent Kits, Diagnostic , Uterine Cervical Neoplasms/pathology
10.
Diagn Cytopathol ; 23(1): 14-8, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10907925

ABSTRACT

Poorly differentiated neuroendocrine (small-cell) carcinoma of cervical origin is a rare neoplasm that frequently metastasizes. Although the cytologic features have been described for conventional cervical smears, we know of no reports of its appearance in ThinPrep (TP) material. Therefore, we present a TP case of primary, small-cell carcinoma arising in a 46-yr-old female, confirmed by histologic and immunohistochemical analysis. Similar to conventional smears, the neoplastic cells occurred either individually or in small clusters. The cells were relatively monomorphic, with stippled chromatin and minimal amounts of cytoplasm. Unlike conventional smears, nuclear molding was not prominent (although overlap was observed), and nuclear smearing was not identified. The features are compared to TP cases of squamous-cell carcinoma, small-cell type, and endometrioid adenocarcinoma, which are close mimics of small-cell carcinoma. We conclude that correct diagnosis of small-cell carcinoma in TP is difficult, requiring a high degree of suspicion and immunohistochemical confirmation.


Subject(s)
Carcinoma, Small Cell/pathology , Uterine Cervical Neoplasms/pathology , Carcinoma, Small Cell/classification , Carcinoma, Small Cell/therapy , Carcinoma, Squamous Cell/classification , Carcinoma, Squamous Cell/pathology , Endometrial Neoplasms/classification , Endometrial Neoplasms/pathology , Female , Humans , Middle Aged , Reagent Kits, Diagnostic , Uterine Cervical Neoplasms/classification , Uterine Cervical Neoplasms/therapy , Vaginal Smears/methods
11.
Am J Surg Pathol ; 22(12): 1449-62, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9850171

ABSTRACT

Prognostic data for ovarian mucinous carcinoma are limited and difficult to interpret because of differing diagnostic criteria and inclusion of secondary tumors. To better characterize these neoplasms, 49 primary ovarian mucinous tumors diagnosed as carcinoma by the Hart and Norris criteria and staged by the FIGO system were studied. Forty-four tumors (90%) were stage I, four were stage III and one was unstaged. Sixteen tumors (33%) were classified as intraglandular ("noninvasive") carcinoma; all were stage I and all patients were alive without tumor after 4-216 months (mean, 74 months); two patients had received adjuvant chemotherapy. Stromal invasion was present in the remaining 33 cases (67%), including 19 tumors with extensive invasion and 14 with one or more discrete foci of microinvasion (each focus < or = 1 mm). The microinvasive tumors were reclassified into intraglandular carcinoma with microinvasion (nine cases) and borderline (low malignant potential) tumor with microinvasion (five cases). All microinvasive tumors were stage I and none recurred after postoperative intervals of 9-176 months (mean, 71 months) for the microinvasive carcinomas and 33-117 months (mean, 60 months) for the microinvasive borderline tumors; only 1 of the 14 patients received adjuvant chemotherapy. All 19 extensively invasive carcinomas also had intraglandular carcinoma. Fourteen were stage I, four were stage III, and one was unstaged. Eleven (79%) of the stage I patients were alive without tumor after 10-220 months (mean, 110 months), including six who received chemotherapy; one was dead without tumor and two developed progressive disease (one had received adjuvant chemotherapy). The four extensively invasive stage III carcinomas were fatal after 1-59 months. The unstaged patient received adjuvant chemotherapy and was alive without recurrence at 98 months. Conclusions of this study are as follows: (1) primary mucinous carcinomas are very uncommon tumors, after rigorous exclusion of metastatic carcinomas and tumors associated with pseudomyxoma peritonei; (2) bilaterality is not a feature of primary mucinous carcinomas; (3) FIGO stage is the single most important prognostic factor, with stage I carcinomas having a very favorable prognosis; (4) stage I carcinomas that metastasize have extensive stromal invasion; (5) extensive stromal invasion is found only in tumors with a component of intraglandular carcinoma; (6) high-stage carcinomas invariably contain extensively invasive carcinoma and have a very poor prognosis; and (7) stromal microinvasion with individual foci not exceeding 1 mm does not appear to be an adverse factor in either carcinomas or borderline tumors of stage I.


Subject(s)
Cystadenocarcinoma, Mucinous/pathology , Ovarian Neoplasms/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Middle Aged , Neoplasm Staging , Prognosis , Stromal Cells/pathology
12.
Vasc Med ; 1(4): 275-80, 1996.
Article in English | MEDLINE | ID: mdl-9552583

ABSTRACT

Activated protein C resistance (APCR) is a recently discovered, medically important cause of venous thrombosis. More than 95% of cases are due to factor V Leiden (FVL), a mutated form of factor V that is resistant to degradation by activated protein C. The prevalence of this disorder, which is inherited in an autosomal dominant fashion, is approximately 5% among asymptomatic people of European heritage. In addition, 20 to 60% of patient cohorts with previous thrombosis demonstrate APCR, making it the most common known genetic cause of abnormal thrombophilia. Current laboratory techniques available for diagnosis include functional assays, such as the APC ratio, as well as DNA-based tests that detect the specific genetic anomaly responsible for FVL. A case report is presented, along with a review of the literature highlighting epidemiology, pathogenesis, clinical features and methods for laboratory diagnosis.


Subject(s)
Protein C/pharmacology , Drug Resistance/physiology , Enzyme Activation , Hemostasis/physiology , Humans , Male , Middle Aged , Protein C/physiology , Thrombophilia/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...